Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 37.96 -1.21 (-3.09%) Market Cap: 2.31 Bil Enterprise Value: 2.11 Bil PE Ratio: 0 PB Ratio: 37.58 GF Score: 50/100

Q2 2023 Rhythm Pharmaceuticals Inc Earnings Call Transcript

Aug 01, 2023 / 12:00PM GMT
Release Date Price: $22.75 (+27.52%)
Operator

Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q2 2023 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Dave Connolly, Executive Director of Investor Relations and Corporate Communications.

David Connolly
Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Thank you, Bella. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section on the Investors' page of our website at ir.rhythmtx.com. This morning, we issued a press release that provides our second quarter 2023 financial results and a business update, which is available on our website.

As listed on Slide 2 is our agenda. Here with me today in Boston are David Meeker, Chair, Chief Executive Officer and President of Rhythm Pharmaceuticals; Jennifer Chien, Executive Vice President, Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot